United States - English - NLM (National Library of Medicine)

cardinal health - risperidone (unii: l6uh7zf8hc) (risperidone - unii:l6uh7zf8hc) - risperidone 0.5 mg

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - risperidone (unii: l6uh7zf8hc) (risperidone - unii:l6uh7zf8hc) - risperdal ® (risperidone) is indicated for the treatment of schizophrenia. efficacy was established in 4 short-term trials in adults, 2 short-term trials in adolescents (ages 13 to 17 years), and one long-term maintenance trial in adults [see clinical studies (14.1)] . monotherapy risperdal ® is indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in 2 short-term trials in adults and one short-term trial in children and adolescents (ages 10 to 17 years) [see clinical studies (14.2)] . adjunctive therapy risperdal ® adjunctive therapy with lithium or valproate is indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in one short-term trial in adults [see clinical studies (14.3)] . risperdal ® is indicated for the

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - risperidone (unii: l6uh7zf8hc) (risperidone - unii:l6uh7zf8hc) - risperdal ® (risperidone) is indicated for the treatment of schizophrenia. efficacy was established in 4 short-term trials in adults, 2 short-term trials in adolescents (ages 13 to 17 years), and one long-term maintenance trial in adults [see clinical studies (14.1)] . monotherapy risperdal ® is indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in 2 short-term trials in adults and one short-term trial in children and adolescents (ages 10 to 17 years) [see clinical studies (14.2)] . adjunctive therapy risperdal ® adjunctive therapy with lithium or valproate is indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in one short-term trial in adults [see clinical studies (14.3)] . risperdal ® is indicated for the

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - baclofen - oral tablet - 10mg

United States - English - NLM (National Library of Medicine)

puracap pharmaceutical llc - benzoyl peroxide (unii: w9wzn9a0gm) (benzoyl peroxide - unii:w9wzn9a0gm) - acne treatment for the treatment of acne

United States - English - NLM (National Library of Medicine)

puracap pharmaceutical llc - salicylic acid (unii: o414pz4lpz) (salicylic acid - unii:o414pz4lpz) - acne treatment for the treatement of acne

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

denk pharma gmbh & co. kg - tramadol (tramadol hydrochloride), paracetamol - tablets film-coated - 37,5mg+ 325mg

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - dobutamine hydrochloride - concentrate for soln for inf - 12.5 mg/ml

New Zealand - English - Medsafe (Medicines Safety Authority)

max health limited - dobutamine hydrochloride 14 mg/ml equivalent to dobutamine 12.5 mg/ml, 250 mg dobutamine in 20 ml;   - concentrate for infusion - 12.5 mg/ml - active: dobutamine hydrochloride 14 mg/ml equivalent to dobutamine 12.5 mg/ml, 250 mg dobutamine in 20 ml   excipient: hydrochloric acid sodium metabisulfite water for injection - dobutamine hydrochloride is indicated when inotropic support is necessary for the treatment of patients with hypoperfusion states in whom cardiac output is insufficient to meet circulatory demands. dobutamine hydrochloride is also indicated when inotropic support is required for the treatment of patients in whom abnormally increased ventricular filling pressures introduce the risk of pulmonary congestion and oedema. conditions which may precipitate such situations include the following hypoperfusion states: initially cardiac in origin: a. acute heart failure acute myocardial infarction, cardiogenic shock, following cardiac surgery, medicine-induced depression of cardiac contractility such as that which occurs in excessive ?-adrenergic receptor blockade. b. chronic heart failure acute decompensation of chronic congestive heart failure, temporary inotropic support in advanced chronic congestive heart failure, as an adjunct to therapy with conventional oral inotropic agents, systemic vasodilators, and diuretics. initially noncardiac in origin: acute hypoperfusion states secondary to trauma, surgery, sepsis, or hypovolaemia when mean arterial pressure is above 70-mm hg and pulmonary capillary wedge pressure is 18-mm hg or greater, with inadequate response to volume repletion and increased ventricular filling pressure, low cardiac output secondary to mechanical ventilation with positive end-expiratory pressure (peep). paediatric population: dobutamine is indicated in all paediatric age groups (from neonates to 18 years of age) as inotropic support in low cardiac output hypoperfusion states resulting from decompensated heart failure, following cardiac surgery, cardiomyopathies and in cardiogenic or septic shock. dobutamine stress echocardiography: dobutamine hydrochloride may be used as a substitute for physical exercise in stress testing in the diagnosis of coronary artery disease. precautions apply (refer to data sheet).

Ireland - English - HPRA (Health Products Regulatory Authority)

mercury pharmaceuticals (ireland) ltd - dobutamine hydrochloride - concentrate for solution for infusion - 12.5 milligram(s)/millilitre - dobutamine